Home » Stocks » DFFN

Diffusion Pharmaceuticals, Inc. (DFFN)

Stock Price: $0.610 USD -0.037 (-5.77%)
Updated May 13, 2021 3:32 PM EDT - Market open
Market Cap 67.59M
Revenue (ttm) n/a
Net Income (ttm) -18.22M
Shares Out 83.42M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $0.610
Previous Close $0.648
Change ($) -0.037
Change (%) -5.77%
Day's Open 0.640
Day's Range 0.600 - 0.650
Day's Volume 1,294,395
52-Week Range 0.600 - 1.850

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients. Data from the open-label stu...

3 days ago - Benzinga

CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies th...

3 days ago - GlobeNewsWire

CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies th...

3 days ago - GlobeNewsWire

Biotech penny stocks are back in focus; should these 3 be on your watchlist? The post Top Biotech Penny Stocks on Reddit?

Other stocks mentioned: AIKI, ATOS
1 week ago - PennyStocks

CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...

1 month ago - GlobeNewsWire

CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...

1 month ago - GlobeNewsWire

CHARLOTTESVILLE, Va., March 04, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...

2 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies t...

2 months ago - GlobeNewsWire

No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Re...

2 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing no...

3 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing no...

3 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwr...

4 months ago - GlobeNewsWire

Initiated and Advanced C linical Trial Evaluating Lead Product Candidate in COVID-19 Patients

6 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D. to ...

6 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (N asdaq : DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D., to the p...

7 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C. Wainwrigh...

8 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who ha...

8 months ago - GlobeNewsWire

Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial

8 months ago - GlobeNewsWire

Continues global clinical development of TSC for the treatment of COVID-19 Continues global clinical development of TSC for the treatment of COVID-19

9 months ago - GlobeNewsWire

Diffusion Pharmaceuticals (NASDAQ: DFFN) shares are trading lower on Monday after the company received guidance from the FDA on the company's IND for trans sodium crocetinate in Covid-19 patients.

9 months ago - Benzinga

Guidance being incorporated into global study protocol Enrollment of first patient now expected in August

9 months ago - GlobeNewsWire

Phase 1b dosing expected to begin this month  Data read-out expected later this quarter

10 months ago - GlobeNewsWire

Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected to enroll 224 patients over 12 months, with 24 patients immediately U.S. IND filing planned for later this month Dosing expe...

11 months ago - GlobeNewsWire

Share price exceeds $1 at closing for 10 consecutive trading days Share price exceeds $1 at closing for 10 consecutive trading days

11 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) shares pushed higher to start the week after the company announced a critical update from the U.S.

11 months ago - 24/7 Wall Street

CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for ...

11 months ago - GlobeNewsWire

Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles

1 year ago - GlobeNewsWire

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares were more than doubling Wednesday following an announcement by the company regarding testing of its lead asset for COVID-19-related complications.

1 year ago - Benzinga

Partnering with University of Virginia Health and iTHRIV Partnering with University of Virginia Health and iTHRIV

1 year ago - GlobeNewsWire

Overtaxed healthcare systems will delay enrollment in some geographic locations Overtaxed healthcare systems will delay enrollment in some geographic locations

1 year ago - GlobeNewsWire

Dr. Gainer to remain on board of directors Dr. Gainer to remain on board of directors

1 year ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for...

1 year ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company developing...

1 year ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously an...

1 year ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), please note that the pricing and fig...

1 year ago - GlobeNewsWire

Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Drug Development Summit Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Dr...

1 year ago - GlobeNewsWire

Diffusion Pharmaceuticals is a tiny micro-cap with market cap between $4.6m and $11.1m (based on a price of $0.285), developing an add-on treatment for brain cancer (glioblastoma) and stroke.

1 year ago - Seeking Alpha

Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Development Summit Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Development Summit

1 year ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company developin...

1 year ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new treatments f...

1 year ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical condi...

1 year ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical cond...

1 year ago - GlobeNewsWire

Year to date, the market has gifted investors a 9.92% return, but it remains off 5.73% from the start of the fourth quarter. While many investors are enjoying a lift in their stocks, the Ben Graham Scre...

Other stocks mentioned: ECOR, SPEX
2 years ago - Forbes

About DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Industry
Biotechnology
Founded
2001
Stock Exchange
NASDAQ
Ticker Symbol
DFFN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for DFFN stock is "Hold" and the 12-month stock price forecast is 2.00.

Price Target
$2.00
Analyst Consensus: Hold